GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANIP · Sep 30, 2023

ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001023024-23-000043General Corporate
Debt relative to revenue40thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.debt_to_revenue

216.86% · OPTIONAL · VALID

Capex intensity15thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.32% · OPTIONAL · VALID

Operating cash generation75thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

24.40% · OPTIONAL · VALID

Revenue growth85thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

57.27% · CORE · VALID

Inventory pressure35thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

80.85% · OPTIONAL · VALID

Operating margin80thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

13.61% · CORE · VALID

R&D intensity70thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

8.44% · OPTIONAL · VALID

SBC intensity25thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4.13% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition

What moved in the state?

Balance Sheet Leverage Decreased
Previous
245.48%
Current
216.86%
Delta
-28.62%
Capex Intensity Decreased
Previous
2.15%
Current
1.32%
Delta
-0.83%
Cash Generation Increased
Previous
17.70%
Current
24.40%
Delta
6.70%
Growth Decreased
Previous
57.81%
Current
57.27%
Delta
-0.53%
Inventory Pressure Decreased
Previous
89.51%
Current
80.85%
Delta
-8.66%
Profitability Increased
Previous
10.64%
Current
13.61%
Delta
2.97%
R And D Intensity Increased
Previous
6.33%
Current
8.44%
Delta
2.11%
Sbc Intensity Decreased
Previous
4.50%
Current
4.13%
Delta
-0.37%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ANIP Fundamental State →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_DECREASED →Transitioned To · ANIP CASH_GENERATION_INCREASED →Transitioned To · ANIP GROWTH_DECREASED →Transitioned To · ANIP INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIP PROFITABILITY_INCREASED →Transitioned To · ANIP R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIP SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.